Skip to main content

regdanvimab (Regkirona®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion due to NICE: Treatments being monitored by RAPID C-19

Medicine details

Medicine name regdanvimab (Regkirona®)
Formulation 60 mg/mL concentrate for solution for infusion
Reference number 5034
Indication

Treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19

Company Celltrion Healthcare Co Ltd
BNF chapter Infections
Assessment type N/A
Status Excluded due to NICE appraisal
Date of issue 13/01/2022
NICE guidance

Treatments being monitored by RAPID C-19

Follow AWTTC: